Safety Alerts & Recalls
What does this mean?
This recall for Avalide tablets from Bristol-Myers Squibb Co. was issued at a warehouse and pharmacy level only. That said, it is possible that pharmacy supplies may be temporarily disrupted as a result of this recall. Your pharmacist may need to dispense two separate medicines, Avapro (irbesartan) and hydrochlorothizide, in place of Avalide if supplies run low. If supplies of Avalide are not available, your doctor will need to provide new prescriptions for the two separate medicines. Since Avalide is a combination product, taking both medicines separately should result in a similar level of blood pressure control. Please follow up with your pharmacist or doctor if you have concerns about your Avalide supply.
To learn more about this recall or the Avalide voucher program, please contact Bristol-Myers Squibb Co. by calling 1-800-332-2056 (option 1, option 4).
Bristol-Myers Squibb Recalls Additional Avalide Tablets
Following on from a recall in September last year, Bristol-Myers Squibb Co. has recalled another 65 more lots of its blood pressure medicine Avalide based on worries that the combination pills aren't delivering proper amounts of one active ingredient, irbesartan. Although the company has not received reports of safety problems and has not found evidence that the tablets are less effective at lowering blood pressure, the company has issued the recall because they are unable to rule out that possibility.
This expanded recall may result in a shortage of Avalide over the coming weeks. Since Avalide is a combination of two medicines, irbesartan and hydrochlorothiazide, patients may be dispensed Avapro (irbesartan) plus Hydrochlorothiazide (HCTZ) as two separate medicines if supplies are disrupted. To support patients in the United States, Bristol-Myers Squibb Co. announced that it will make vouchers available to help defray the cost of hydrochlorothiazide.
For information about this recall, please visit: more information here
To learn about the voucher program, please visit: more information here